Alzheimer’s trial to test drug on people without symptoms to see if it can be prevented

Roche stands to gain a landmark preventive treatment while patients and health systems could avoid the costly progression of Alzheimer's, as the company launches a world‑first trial offering its drug to asymptomatic, middle‑aged adults. The trial targets healthy individuals before any memory loss appears, directly addressing the disease’s preventive gap. If successful, the approach could shift the economic burden of dementia.

Business News Nigeria reported that the drug cleared amyloid plaques in 28 weeks and is slated for a 2028 study to test slowing of memory loss. The Telegraph noted that healthy middle‑aged volunteers are being recruited, and express.co.uk said the regimen will be offered to over‑55s across the UK. The BBC observed an NHS trust joining the study, underscoring institutional backing and early adoption by the health system.

The Guardian warned that testing the drug on people without symptoms means its preventive efficacy is still unproven and results are pending. No timeline for outcomes is provided, and the trial’s design limits conclusions to the specific age group enrolled, leaving regulatory approval dependent on future data. Clinical relevance will be evaluated.